高级检索
当前位置: 首页 > 详情页

The Prognostic Value of Serum Apolipoprotein A-I Level and Neutrophil-to-Lymphocyte Ratio in Colorectal Cancer Liver Metastasis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510403 Guangdong, China [2]Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, 510403 Guangdong, China [3]Department of Hepatobiliary Surgery, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405 Guangdong, China [4]Cancer Center, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405 Guangdong, China [5]Department of Endocrinology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405 Guangdong, China [6]Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, 510120 Guangdong, China [7]Postdoctoral Research Station, Guangzhou University of Chinese Medicine, Guangzhou, China
出处:
ISSN:

摘要:
Background. Colorectal cancer liver metastasis (CRLM) is a high degree of malignancy with rapid disease progression and has a poor prognosis. Both serum apolipoprotein A-I (ApoA-I) and neutrophil-to-lymphocyte ratio (NLR) play key roles in anti-inflammation and antitumor. This study is aimed at evaluating the implication of serum ApoA-I level in combination with NLR in the prognosis of CRLM. Methods. We retrospectively analyzed the serum ApoA-I level and NLR in 237 patients with CRLM. Cox regression analyses were used to identify the independent prognostic significance of these indicators. Kaplan-Meier method and Log-rank test were applied to compute overall survival (OS). Both the ApoA-I and NLR were divided into three levels, according to their medians. A risk-stratified prediction model was established to evaluate the prognosis of patients with CRLM. The ROC curve AUC values were applied to evaluate the capability of the model. Results. Higher levels of ApoA-I and lower NLR were strongly associated with prolonged OS (Log-rank test, P < 0.05). The patients were then grouped into three queues according to the ApoA-I level and NLR. There was a crucial diversity in the OS (P < 0.001) between the high-risk (ApoA - I < 1.03 g/L and NLR > 3.24), medium-risk (ApoA - I > 1.03 g/L or NLR < 3.24) and low-risk groups (ApoA - I > 1.03 g/L and NLR < 3.24). The AUC value of the prediction model (AUC = 0.623, 95% CI: 0.557-0.639, P = 0.001) was higher than other individual indicators (including ApoA-I, NLR, cT classification, and cN classification). Additionally, the association of the prediction model and cTN classification (AUC = 0.715, 95% CI: 0.606-0.708, P < 0.001) was better than the model and cTN classification alone. Conclusion. The combination of ApoA-I level and NLR could be a prognostic indicator for CRLM.

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
JCR分区:
出版当年[2020]版:
Q2 ONCOLOGY
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510403 Guangdong, China [2]Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, 510403 Guangdong, China [3]Department of Hepatobiliary Surgery, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405 Guangdong, China
共同第一作者:
通讯作者:
通讯机构: [2]Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, 510403 Guangdong, China [3]Department of Hepatobiliary Surgery, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405 Guangdong, China [5]Department of Endocrinology, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405 Guangdong, China [7]Postdoctoral Research Station, Guangzhou University of Chinese Medicine, Guangzhou, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号